Voronoi, Inc. акциялары

Voronoi, Inc., founded in 2015 and based in Incheon, South Korea, is a biotechnology company dedicated to the research, development, and identification of small molecule kinase inhibitors. Its extensive product pipeline addresses various medical needs. Key candidates include VRN01, an oral leucine-rich repeat kinase 2 (LRRK2) inhibitor, being developed for glioblastoma multiforme, brain cancer, and pancreatic cancer. Treatments for lung cancer are represented by VRN07, VRN06, and VRN11, while VRN08 and VRN10 are in development for breast cancer. Additionally, VRN02 targets rheumatoid arthritis and atopic dermatitis. The company's pipeline further encompasses VRN04-1 for autoimmune conditions, VRN04-2 for multiple sclerosis and amyotrophic lateral sclerosis (ALS), VRN13 for pulmonary arterial hypertension, and VRN14 for challenging solid tumors.